119 related articles for article (PubMed ID: 11424018)
1. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study.
Spruance SL; Tyring SK; Smith MH; Meng TC
J Infect Dis; 2001 Jul; 184(2):196-200. PubMed ID: 11424018
[TBL] [Abstract][Full Text] [Related]
2. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial.
Mark KE; Corey L; Meng TC; Magaret AS; Huang ML; Selke S; Slade HB; Tyring SK; Warren T; Sacks SL; Leone P; Bergland VA; Wald A
J Infect Dis; 2007 May; 195(9):1324-31. PubMed ID: 17397003
[TBL] [Abstract][Full Text] [Related]
3. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment.
Bernstein DI; Harrison CJ; Tomai MA; Miller RL
J Infect Dis; 2001 Mar; 183(6):844-9. PubMed ID: 11237799
[TBL] [Abstract][Full Text] [Related]
4. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses.
Wu JJ; Huang DB; Tyring SK
Antiviral Res; 2004 Nov; 64(2):79-83. PubMed ID: 15498602
[TBL] [Abstract][Full Text] [Related]
5. Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions.
Fife KH; Meng TC; Ferris DG; Liu P
Antimicrob Agents Chemother; 2008 Feb; 52(2):477-82. PubMed ID: 18039918
[TBL] [Abstract][Full Text] [Related]
6. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
7. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
Fife KH; Warren TJ; Justus SE; Heitman CK;
Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
[TBL] [Abstract][Full Text] [Related]
8. Three phase III randomized controlled trials of topical resiquimod 0.01-percent gel to reduce anogenital herpes recurrences.
Mark KE; Spruance S; Kinghorn GR; Sacks SL; Slade HB; Meng TC; Selke S; Magaret A; Wald A
Antimicrob Agents Chemother; 2014 Sep; 58(9):5016-23. PubMed ID: 24709264
[TBL] [Abstract][Full Text] [Related]
9. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects.
DeJesus E; Wald A; Warren T; Schacker TW; Trottier S; Shahmanesh M; Hill JL; Brennan CA;
J Infect Dis; 2003 Oct; 188(7):1009-16. PubMed ID: 14513421
[TBL] [Abstract][Full Text] [Related]
10. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection.
Wald A; Carrell D; Remington M; Kexel E; Zeh J; Corey L
Clin Infect Dis; 2002 Apr; 34(7):944-8. PubMed ID: 11880960
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the activity and safety of CS21 barrier genital gel® compared to topical aciclovir and placebo in symptoms of genital herpes recurrences: a randomized clinical trial.
Khemis A; Duteil L; Tillet Y; Dereure O; Ortonne JP
J Eur Acad Dermatol Venereol; 2014 Sep; 28(9):1158-64. PubMed ID: 24010876
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study.
Schacker TW; Conant M; Thoming C; Stanczak T; Wang Z; Smith M
Antimicrob Agents Chemother; 2002 Oct; 46(10):3243-8. PubMed ID: 12234851
[TBL] [Abstract][Full Text] [Related]
13. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis.
Szeimies RM; Bichel J; Ortonne JP; Stockfleth E; Lee J; Meng TC
Br J Dermatol; 2008 Jul; 159(1):205-10. PubMed ID: 18476957
[TBL] [Abstract][Full Text] [Related]
14. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment.
Leone PA; Trottier S; Miller JM
Clin Infect Dis; 2002 Apr; 34(7):958-62. PubMed ID: 11880962
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.
Warren T; Harris J; Brennan CA
Clin Infect Dis; 2004 Nov; 39 Suppl 5():S258-66. PubMed ID: 15494897
[TBL] [Abstract][Full Text] [Related]
16. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.
Handsfield HH; Warren T; Werner M; Phillips JA
Sex Transm Dis; 2007 Jun; 34(6):339-43. PubMed ID: 17065847
[TBL] [Abstract][Full Text] [Related]
17. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women.
Andrews WW; Kimberlin DF; Whitley R; Cliver S; Ramsey PS; Deeter R
Am J Obstet Gynecol; 2006 Mar; 194(3):774-81. PubMed ID: 16522412
[TBL] [Abstract][Full Text] [Related]
18. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.
Sheffield JS; Hill JB; Hollier LM; Laibl VR; Roberts SW; Sanchez PJ; Wendel GD
Obstet Gynecol; 2006 Jul; 108(1):141-7. PubMed ID: 16816068
[TBL] [Abstract][Full Text] [Related]
19. Acyclovir suppression to prevent recurrent genital herpes at delivery.
Scott LL; Hollier LM; McIntire D; Sanchez PJ; Jackson GL; Wendel GD
Infect Dis Obstet Gynecol; 2002; 10(2):71-7. PubMed ID: 12530483
[TBL] [Abstract][Full Text] [Related]
20. Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial.
Hull C; McKeough M; Sebastian K; Kriesel J; Spruance S
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):263-7. PubMed ID: 19143902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
